• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket

    5/31/23 8:39:27 AM ET
    $ACON
    $ACRX
    $AMBA
    $ASPI
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • VIQ Solutions Inc. (NASDAQ:VQS) shares rose 66.8% to $0.3887 in pre-market trading.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) shares surged 59% to $0.4307 in pre-market trading after dropping 14% on Tuesday.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) shares rose 50% to $0.2009 in pre-market trading. Vistagen will present fasedienol safety and exploratory efficacy data from Phase 3 Open-label social anxiety disorder study at the American Society for Clinical Psychopharmacology Annual Meeting.
    • WANG & LEE GROUP, Inc. (NASDAQ:WLGS) gained 27.3% to $1.77 in pre-market trading after declining around 5% on Tuesday.
    • LL Flooring Holdings, Inc. (NYSE:LL) shares gained 19.1% to $4.93 in pre-market trading. LL Flooring confirmed the receipt of $5.76 per share unsolicited, non-binding proposal from Cabinets To Go, a subsidiary of F9 Brands.
    • Edgio, Inc. (NASDAQ:EGIO) rose 14.1% to $0.5650 in pre-market trading.
    • Mobilicom Limited (NASDAQ:MOB) rose 13.2% to $1.54 in pre-market trading after gaining 7% on Tuesday. Mobilicom recently received a purchase order for its end-to-end product solution that will be installed into autonomous and remote-controlled electric vehicles for homeland security and defense.
    • Netcapital Inc. (NASDAQ:NCPL) gained 10.1% to $1.42 in pre-market trading after declining 7% on Tuesday. The company recently reported closing of registered direct offering.
    • Micromobility.com Inc. (NASDAQ:MCOM) shares climbed 10.1% to $0.40 in pre-market trading after dropping around 6% on Tuesday. The company recently posted a rise in quarterly sales.
    • Recruiter.com Group, Inc. (NASDAQ:RCRT) shares gained 9.6% to $0.2465 in pre-market trading after gaining 4% on Tuesday. Recruiter.com, last month, announced the launch of Candidate Pitch, an AI web application.

    Losers

    • Belite Bio, Inc (NASDAQ:BLTE) fell 37.2% to $14.76 in pre-market after the company reported pricing of $30 million underwritten public offering of American Depositary Shares and warrants.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares dropped 31.6% to $0.0928 in pre-market trading. Biodexa Pharmaceuticals recently reported closing of $3.32 million registered direct offering.
    • Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares dropped 26.1% to $0.5675 in pre-market trading.
    • QualTek Services Inc (NASDAQ:QTEK) fell 19.3% to $0.12 in pre-market trading after jumping 96% on Tuesday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
    • Wejo Group Ltd (NASDAQ:WEJO) fell 19.2% to $0.10 in pre-market trading. Wejo Group shares dipped 57% on Tuesday after the company said it is evaluating whether to file ancillary insolvency proceedings for the company and other units in other jurisdictions, including the US.
    • AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) fell 18.6% to $0.80 in pre-market trading after declining 11% on Tuesday. AcelRx Pharmaceuticals recently posted a narrower-than-expected quarterly loss.
    • Ambarella Inc (NASDAQ:AMBA) fell 17.9% to $67.30 in pre-market trading after the company issued a weak second-quarter forecast.
    • ASP Isotopes Inc (NASDAQ:ASPI) shares fell 13.5% to $0.30 in pre-market trading after gaining 6% on Tuesday.
    • UTime Ltd (NASDAQ:UTME) fell 12.7% to $1.31 in pre-market trading after jumping 30% on Tuesday.
    • Aclarion Inc (NASDAQ:ACON) fell 10.5% to $0.94 in pre-market trading. Aclarion shares jumped 78% on Tuesday after the company announced a commercial agreement with the London Clinic and London Spine Clinic.

     

    Now Read This: Investor Optimism Declines After Dow Settles Lower

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ACRX
    $AMBA
    $ASPI

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mobilicom to Exhibit at Modern Day Marine 2026, Showcasing its Cybersecure Solutions Portfolio Amid Growing U.S. Department of War Platform Deployments

    Mobilicom to hold strategic meetings with U.S. Department of War and Marine Corps representatives, as well as existing customers and new customers under integration, at the premier Marine Corps technology exposition Palo Alto, California, April 23, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW)) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, today announced it will exhibit at Modern Day Marine 2026, taking place April 28–30, 2026 in Washington, D.C. The Company will exhibit under the booth of its strategic U.S. partner, Noble, a leading provider of procurement and logistics for the defense industry, at Booth #618.

    4/23/26 9:15:00 AM ET
    $MOB
    Aerospace
    Industrials

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, April 28, 2026 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in Australia, China, Hong Kong, Portugal, Netherlands, Cayman Islands and France, will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live presentations and/or ask qu

    4/23/26 8:35:00 AM ET
    $BLTE
    $HCM
    $LOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    Belite Bio to Participate in Four Upcoming Investor Conferences

    SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in four upcoming investor conferences. Details of the presentations are as follows:   Deutsche Bank American Depositary Receipt Virtual Investor Conference (Virtual) April 28, 2026, at 9:00 am ET, corporate presentation BofA Securities 2026 Health Care Conference (Las Vegas, NV) May 13, 2026, at 3:40 pm PT, fireside chat H.C. Wainwright 4th Annual BioConnect Nasdaq Inves

    4/23/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Mata Nathan L. sold $166,284 worth of American depositary share (1,000 units at $166.28) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 9,666 units (SEC Form 4)

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/24/26 4:15:07 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Lin Yu-Hsin acquired 10,000 units of Ordinary Share, increasing direct ownership by 6% to 182,949 units (SEC Form 4)

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/23/26 4:23:00 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Scholl Hendrik Peter

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/23/26 4:20:10 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACRX
    $AMBA
    $ASPI
    SEC Filings

    View All

    SEC Form 6-K filed by Mobilicom Limited

    6-K - Mobilicom Ltd (0001898643) (Filer)

    4/23/26 9:17:13 AM ET
    $MOB
    Aerospace
    Industrials

    Aclarion Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Aclarion, Inc. (0001635077) (Filer)

    4/22/26 9:00:17 AM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Belite Bio Inc

    6-K - BELITE BIO, INC (0001889109) (Filer)

    4/21/26 4:00:16 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:49 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:33 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Netcapital Appoints Todd Violette as Chief Executive Officer

    BOSTON, MA, April 16, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a publicly traded fintech company that gives companies access to capital markets infrastructure without institutional-scale fees, today announced that its Board of Directors has appointed Mr. Violette to lead the Company in order to accelerate capital formation, expand platform reach, and build long-term shareholder value. Mr. Violette brings over 25 years of leadership experience across capital markets, fintech and digital asset-related businesses. His recent operating and executive roles have included CEO of CloudCover International, CEO of AppYea Inc., CEO of Vinergy, Chief Investment

    4/16/26 4:05:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Leap Energy Appoints Nate Salpeter, Ph.D., a Key Opinion Leader in Fluid Dynamics and Energy Technology, as its Chief Technology Officer

    DALLAS, March 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Nate Salpeter, Ph.D. as its Chief Technology Officer. Dr. Salpeter is a recognized key opinion leader in the field of physics-constrained energy technology optimization, with more than 15 years of experience building computational frameworks, laser-based experimental methods, and first-of-kind engineering programs across nuclear energy and advanced thermal sys

    3/5/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Financials

    Live finance-specific insights

    View All

    ASP Isotopes Inc. Provides Business Update

    First Commercial Shipments Expected Across Multiple Isotopes in 2026 Expect to Obtain Helium Phase 1 Nameplate Capacity in Q3 2026 EBITDA Target of Greater Than $300 Million in 2031 Cash, Cash Equivalents and Short-Term Marketable Securities of $333 million as of December 31, 2025 Business Update Conference Call Scheduled for 8:00 AM ET on April 13, 2026 DALLAS, April 13, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today provided a business update highlighting operational

    4/13/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes to Host Business Update Conference Call on April 13, 2026, at 8:00 AM ET

    DALLAS, April 10, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today announced that Paul Mann, Executive Chairman and Chief Executive Officer at ASP Isotopes, will host a business update conference call and webcast on Monday, April 13, 2026, at 8:00 AM ET. Dial-in Information USA / International Toll: +1.646.968.2525USA - Toll-Free: +1.888.596.4144Canada - Toronto: +1.647.495.7514Canada - Toll-Free: +1.888.596.4144Conference ID 5073116 and press # Investors and the general public are invited to

    4/10/26 8:15:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Mobilicom Reports 2025 Year-End Financial Results

    A Mobilicom Tier-1 defense customer won a U.S. Department of War (DoW) Program of Record, indicating a potential production scale orders for the next 5 years  Cash and cash equivalents surge 120% to $19.1 million following $12.6 million in 2025 warrants exercise and equity raises With revenues up year-over-year at $3.4 million, monthly operating cash burn was cut by 41% to ~$159K — lowest in Company history — with zero-debt on balance sheet Launch of industry-first Secured Autonomy™ cybersecurity framework, multiple new design wins across Europe, Middle East and South Asia, and expanded U.S. Tier-1 drone production-scale orders drive multi-market momentum Webcast scheduled for 4:30 pm E

    3/23/26 4:06:00 PM ET
    $MOB
    Aerospace
    Industrials

    $ACON
    $ACRX
    $AMBA
    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 7:25:20 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care